Chemexpress(SH:688131) Jing Ji Guan Cha Wang·2026-02-11 09:34Group 1 - The company expects to procure chemical raw materials from its affiliate Gansu Haotian Technology Co., Ltd. with a maximum amount of 50 million yuan by 2026 [1] - The company plans to sell products and provide technical services to a new affiliate, Hangzhou Jiaolian Biomedical Technology Co., Ltd., with a maximum amount of 10 million yuan [1] - These transactions are based on daily operational needs and are expected to be executed within the board's approval authority [1] Group 2 - The company continues to expand in cutting-edge fields such as XDC, PROTAC, peptides, and small nucleic acid drugs, aiming to build an integrated service capability from laboratory to commercial production [2] - Long-term trends such as policy support for the pharmaceutical industry and population aging may present opportunities for the company's innovative drug research and development [2] Group 3 - The pharmaceutical and biotechnology industry is significantly influenced by policies, such as adjustments to medical insurance catalogs and the pace of review and approval for innovative drugs, which may indirectly affect the business demand for the company as a medical research outsourcing entity [3]